Please enable Javascript
Hans Hammers, MD, PhD
Hans Hammers, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center
Articles by Hans Hammers, MD, PhD
RCC Panel Shares What They Are Most Excited About in the Field
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
View More
Phase 2 TIDE-A Study: Thoughts and Potential Treatment Impacts
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
View More
RCC Panel Reacts to LITESPARK-005 Data Presented at ESMO 2023
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
View More
Focus on Nonclear Cell RCC: Frontline Treatment Options, Research Limitations, and More
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel talks about nonclear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
View More
Panel Discusses the Value of Immunotherapy in Frontline RCC
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel addresses the place for immune monotherapy, as well as takeaways from trials like PDIGREE, PROBE, and more.
View More
ESMO 2023: RENOTORCH Assesses Toripalimab and Axitinib in RCC
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for RCC.
View More
Frontline Clear Cell Kidney Cancer: Treatment Selection and Patient Considerations
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel shared their approach to treatment selection for clear cell kidney cancer.
View More
Hans Hammers, MD, PhD – Driving Immunotherapy Combinations Into the Modern Age of Kidney Cancer Care
Hans Hammers, MD, PhD
Renal Cell Carcinoma
|
September 8, 2023
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
Read More